MEDNAX INC's gross profit margin for the second quarter of its fiscal year 2015 is essentially unchanged when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. MEDNAX INC has average liquidity. Currently, the Quick Ratio is 1.45 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 7.66% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY15||Q2 FY14|
|Net Sales ($mil)||676.59||595.55|
|Net Income ($mil)||84.13||79.02|
|Balance Sheet||Q2 FY15||Q2 FY14|
|Cash & Equiv. ($mil)||70.43||25.28|
|Total Assets ($mil)||4275.14||3174.5|
|Total Debt ($mil)||1296.9||178.69|
|Profitability||Q2 FY15||Q2 FY14|
|Gross Profit Margin||33.83||33.73|
|Return on Assets||7.65||9.4|
|Return on Equity||14.75||12.42|
|Debt||Q2 FY15||Q2 FY14|
|Share Data||Q2 FY15||Q2 FY14|
|Shares outstanding (mil)||94.03||100.17|
|Div / share||0.0||0.0|
|Book value / share||23.61||24.0|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||638387.0||542046.0|
BUY. The current P/E ratio indicates a discount compared to an average of 27.89 for the Health Care Providers & Services industry and a premium compared to the S&P 500 average of 20.51. To use another comparison, its price-to-book ratio of 3.57 indicates a premium versus the S&P 500 average of 2.73 and a discount versus the industry average of 3.78. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, MEDNAX INC proves to trade at a discount to investment alternatives within the industry.
|MD 25.01||Peers 27.89||MD 18.56||Peers 16.13|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
MD is trading at a discount to its peers.
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
MD is trading at a premium to its peers.
|MD 20.61||Peers 19.57||MD 1.81||Peers 1.72|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
MD is trading at a premium to its peers.
Average. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
MD trades at a valuation on par to its peers.
|MD 3.57||Peers 3.78||MD 13.85||Peers 43.15|
Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
MD is trading at a valuation on par with its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, MD is expected to significantly trail its peers on the basis of its earnings growth rate.
|MD 3.06||Peers 0.88||MD 13.52||Peers 17.56|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
MD is trading at a significant premium to its industry.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
MD trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV